S100G expression and function in fibroblasts on colitis induction

Area of Science:

• Immunology
• Gastroenterology
• Molecular Biology

Background:

• Interleukin-10 (IL-10) is a key anti-inflammatory cytokine.
• IL-10 supplementation has shown limited efficacy in treating inflammatory bowel diseases (IBD).
• The mechanisms underlying IL-10's limited therapeutic effects in IBD require further elucidation.

Purpose of the Study:

• To investigate the role of S100G (Calbindin-D9k) in a mouse model of colitis.
• To determine the regulatory relationship between IL-10 and S100G expression.
• To explore the potential of S100G as an anti-inflammatory mediator in IBD.

Main Methods:

• Induction of colitis in a hapten-protein visualization model.
• Histological and gene expression analyses to assess inflammatory changes.
• Evaluation of S100G expression in fibroblasts and its regulation by IL-10.

Main Results:

• IL-10 deficiency led to reduced inflammatory changes and elevated S100G expression in colitis.
• S100G was expressed in fibroblasts and its expression was suppressed by IL-10.
• S100G inhibited monocyte chemotactic protein-1 (MCP-1) production by suppressing NF-κB activation.

Conclusions:

• S100G acts as an anti-inflammatory mediator in fibroblasts during colitis.
• IL-10 down-regulates S100G expression, potentially contributing to the inefficacy of IL-10 therapy in IBD.
• Targeting S100G may offer a novel therapeutic strategy for IBD.